Marker Therapeutics, Inc. (MRKR)

Market Cap	23.51M +102.7%
Revenue (ttm)	3.55M -46.2%
Net Income	-12.16M
EPS	-0.79
Shares Out	16.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	264,186
Open	1.310
Previous Close	1.320
Day's Range	1.310 - 1.500
52-Week Range	0.810 - 4.070
Beta	1.47
Analysts	Strong Buy
Price Target	10.00 (+609.22%)
Earnings Date	May 14, 2026

About MRKR

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: MRKR
• Website: https://markertherapeutics.com

Financial Performance

In 2025, Marker Therapeutics's revenue was $3.55 million, a decrease of -46.19% compared to the previous year's $6.59 million. Losses were -$12.16 million, 13.3% more than in 2024.

Analyst Summary

According to one analyst, the rating for MRKR stock is "Strong Buy" and the 12-month stock price target is $10.0.

Price Target

$10.0

(609.22% upside)

Analyst Consensus: Strong Buy